Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Nasdaq 100 Movers: MYL, VRTX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2017 | 04:26pm CEST

In early trading on Tuesday, shares of Vertex Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.3%. Year to date, Vertex Pharmaceuticals registers a 106.9% gain.

© BNK Invest, source Videos

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
08/22 NASDAQ 100 MOVERS : Myl, vrtx
08/17 RESEARCHERS FROM CONCERT PHARMACEUTI : ...
08/10 VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® ivacaftor for More Than 600 Peop..
08/07 VERTEX PHARMACEUTICALS : Breakfast Technical Briefing on Biotech Stocks -- Sarep..
08/03 DATA ON GASTROENTEROLOGY REPORTED BY : Impact of Measured,...
08/03 VERTEX PHARMACEUTICALS : and Concert Pharmaceuticals Complete Asset Purchase Agr..
08/03 CONCERT PHARMACEUTICALS : Announces Termination of the HSR Act Waiting Period fo..
08/03 VERTEX PHARMACEUTICALS : Corporate News Blog - Vertex Pharma Announces Approval ..
08/02 VERTEX PHARMACEUTICALS INCORPORATED : - FDA Approves KALYDECO for More Than 600 ..
08/01 VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® (ivacaftor) for More Than 600 Pe..
More news
News from SeekingAlpha
08/13 Vertex Pharmaceuticals May Be Turning Some Major Corners
08/09 VALUATION DASHBOARD : Healthcare - Update
08/07 Vanguard Brings You Healthy Returns With Less Volatility
08/02 Studying Momentum In Health Care Stocks In The S&P 500
08/01 Vertex Pharma raises Kalydeco sales guidance after FDA OKs expanded use
Financials ($)
Sales 2017 2 280 M
EBIT 2017 484 M
Net income 2017 182 M
Finance 2017 727 M
Yield 2017 -
P/E ratio 2017 224,10
P/E ratio 2018 91,92
EV / Sales 2017 16,9x
EV / Sales 2018 14,0x
Capitalization 39 199 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 178 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Senior VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS111.05%39 199
AMGEN14.42%122 702
CELGENE CORPORATION10.09%99 695
GILEAD SCIENCES0.70%94 810
REGENERON PHARMACEUTICALS27.48%50 334
ACTELION22.00%30 289